Skip to main content Back to Top
Advertisement

11/28/2022

Furosemide Injection

Products Affected - Description

    • Furosemide injection, Eugia US, 10 mg/mL, 10 mL vial, 25 count, NDC 55150-0324-25
    • Furosemide injection, Eugia US, 10 mg/mL, 2 mL vial, 25 count, NDC 55150-0322-25
    • Furosemide injection, Eugia US, 10 mg/mL, 4 mL vial, 25 count, NDC 55150-0323-25
    • Furosemide injection, Pfizer, 10 mg/mL, 10 mL Luer Lock syringe, 10 count, NDC 00409-1639-10 - discontinued
    • Furosemide injection, Pfizer, 10 mg/mL, 10 mL vial, 25 count, NDC 00409-6102-10
    • Furosemide injection, Pfizer, 10 mg/mL, 4 mL syringe, 10 count, NDC 00409-9631-04 - discontinued
    • Furosemide injection, Pfizer, 10 mg/mL, 4 mL vial, 25 count, NDC 00409-6102-04

Reason for the Shortage

    • American Regent is not actively marketing furosemide injection.
    • Amneal discontinued furosemide injection.
    • Avet Pharmaceuticals has furosemide injection available.
    • Baxter has furosemide injection available.
    • Eugia has furosemide injection on shortage due to increased demand.
    • Fresenius Kabi has furosemide injection on shortage due to increased demand.
    • Pfizer has furosemide injection on shortage due to increased demand. The 4 mL Ansyr and 10 mL Luer Lock syringes were discontinued in late-2022.
    • Sagent has furosemide injection on shortage due to document review.

Available Products

    • Furosemide injection, Avet Pharmaceuticals, 10 mg/mL, 10 mL vial, 25 count, NDC 23155-0476-41
    • Furosemide injection, Avet Pharmaceuticals, 10 mg/mL, 2 mL vial, 25 count, NDC 23155-0473-41
    • Furosemide injection, Avet Pharmaceuticals, 10 mg/mL, 4 mL vial, 25 count, NDC 23155-0474-41
    • Furosemide injection, Baxter, 10 mg/mL, 10 mL vial, 25 count, NDC 36000-0284-25
    • Furosemide injection, Baxter, 10 mg/mL, 2 mL vial, 25 count, NDC 36000-0282-25
    • Furosemide injection, Baxter, 10 mg/mL, 4 mL vial, 25 count, NDC 36000-0283-25
    • Furosemide injection, Fresenius Kabi, 10 mg/mL, 10 mL vial, 25 count, NDC 63323-0280-10
    • Furosemide injection, Fresenius Kabi, 10 mg/mL, 2 mL vial, 25 count, NDC 63323-0280-02
    • Furosemide injection, Fresenius Kabi, 10 mg/mL, 4 mL vial, 25 count, NDC 63323-0280-04
    • Furosemide injection, Pfizer, 10 mg/mL, 2 mL vial, 25 count, NDC 00409-6102-02
    • Furosemide injection, Sagent, 10 mg/mL, 10 mL vial, 25 count, NDC 25021-0311-10
    • Furosemide injection, Sagent, 10 mg/mL, 2 mL vial, 25 count, NDC 25021-0311-02
    • Furosemide injection, Sagent, 10 mg/mL, 4 mL vial, 25 count, NDC 25021-0311-04

Estimated Resupply Dates

    • Eugia has furosemide 10 mg/mL 4 mL and 10 mL vials on back order and the company cannot estimate a release date. The 2 mL vials are on back order and the company estimates a release date of late-November 2022.
    • Pfizer has furosemide 10 mg/mL 4 mL vials available in limited supply. The 10 mL vials are on back order and the company estimates a release date of November 2022.

Updated

Updated November 28, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. Created May 19, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.